Page last updated: 2024-08-21

indazoles and Cancer of Pancreas

indazoles has been researched along with Cancer of Pancreas in 53 studies

Research

Studies (53)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (3.77)	18.2507
2000's	9 (16.98)	29.6817
2010's	36 (67.92)	24.3611
2020's	6 (11.32)	2.80

Authors

Authors	Studies
Bellesoeur, A; Beuzeboc, P; Diéras, V; Neuzillet, C; Rodrigues, M; Saint-Ghislain, M; Salaün, H; Stern, MH	1
Domchek, SM; Donze, A; Gosselin, MK; Karasic, T; Massa, R; Mick, R; O'Hara, M; Onyiah, C; Reiss, KA; Schneider, C; Teitelbaum, U; Tondon, R; Vonderheide, RH	1
Chamberlain, S; Mole, DR; Protheroe, A; Purshouse, K; Soares, M; Tuthill, M	1
André, T; Cohen, R; Ouali, K; Pellat, A; Penault-Llorca, F; Svrcek, M	1
Fujiwara, K; Ishida, H; Kanamitsu, K; Shimada, A; Tsukahara, H; Washio, K	1
Battistone, B; Garrido-Laguna, I; Ghazi, P; Kinsey, CG; McMahon, M; Parkman, GL; Scherzer, MT; Schuman, S; Truong, A; Vaishnavi, A	1
Aguilar-Valdés, A; Ibarra-Sánchez, MJ; Maravillas-Montero, JL; Martínez-Aguilar, J; Noriega, LG; Sosa-Hernández, VA; Tovar, AR	1
Bhutkar, A; Chen, PY; Chung, KM; Dorans, KJ; Hong, E; Jacks, T; Muzumdar, MD; Noll, EM; Sprick, MR; Trumpp, A	1
Cheng, L; Li, X; Yang, F; Zhang, L	1
Jeon, SY; Lee, NR; Yim, CY	1
Abe, T; Ando, Y; Fei, S; Feng, H; Guan, W; Hashizume, M; Iwamoto, C; Kibe, S; Koikawa, K; Miyasaka, Y; Mizumoto, K; Moriyama, T; Nakamura, M; Nakata, K; Ohtsuka, T; Ohuchida, K; Shindo, K; Yan, Z; Zheng, B	1
Alessi, DR; Arbeiter, A; Baccarini, M; Dobler, M; Eser, S; Esposito, I; Gottschalk, K; Hieber, M; Kind, AJ; Klein, S; Kong, B; Messer, M; Michalski, CW; Rad, L; Rad, R; Reiff, N; Saur, D; Schlitter, AM; Schmid, RM; Schneider, G; Schnieke, AE; Seidler, B	1
Belmont, LD; Fairbrother, WJ; Hong, R; Lee, LB; Nannini, MA; Price, S; Sampath, D; Savy, PP; Settleman, J; Tan, N; Williams, K; Wong, M; Yue, P	1
Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C	1
Chang, LH; Lai, CY; Pan, SL; Teng, CM; Tsai, AC	1
Ahn, HK; Choi, JY; Choi, SH; Kang, WK; Kim, H; Kim, KM; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS	1
Bold, RJ; Coates, J; Muilenburg, D; Parsons, C; Virudachalam, S	1
Avril, N; Hagemann, T; Hudson, CD; Mather, SJ	1
Pattison, S; Zalcberg, JR	1
Bou-Reslan, H; Cao, T; Carano, R; Castillo, J; Chan, E; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, W; French, D; Hoeflich, KP; Junttila, MR; Merchant, M; Metcalfe, C; Nannini, MA; Otter, DD; Singh, M	1
Boku, N; Bycott, P; Fujii, Y; Furuse, J; Ioka, T; Kamei, Y; Namazu, K; Ohkawa, S; Okusaka, T; Sawaki, A; Takahashi, S; Umeyama, Y	1
Cho, IR; Chung, YH; Jung, CR; Kang, HY; Kaowinn, S; Koh, SS; Moon, J; Oh, S; Soh, J; Song, H	1
Chan, JA; Fogelman, DR; Halperin, DM; Hess, KR; Kulke, MH; Malinowski, P; Ng, CS; Phan, AT; Regan, E; Yao, JC	1
Atkinson, BJ; Corn, PG; Jonasch, E; Kalra, S; Karam, JA; Matin, SF; Matrana, MR; Rao, P; Sircar, K; Tamboli, P; Tannir, NM; Wood, CG	1
Alonso-Gordoa, T; Apellaniz-Ruiz, M; Capdevila, J; Carrato, A; Casanovas, O; Castellano, D; Díez, JJ; Durán, I; Earl, J; Escudero, P; Fuster, J; García-Carbonero, R; García-Donas, J; Grande, E; Ortega, L; Rodriguez-Antona, C; Sastre, J; Sevilla, I; Teulé, A	1
Behzadigohar, R; Rosenthal, MA; Tran, B	1
Devriese, LA; Giantonio, BJ; Kerklaan, BM; Lane, S; Langenberg, M; Legenne, P; Lolkema, MP; Mergui-Roelvink, M; Mykulowycz, K; Nol-Boekel, A; Schellens, JH; Smith, DA; Stoebenau, J; Voest, EE; Wissel, P; Witteveen, PO	1
Abdollahi, A; Alves, F; Chiblak, S; Fuchs, B; Jannasch, K; Kleeff, J; Lindner, T; Matzke-Ogi, A; Mier, W; Morton, J; Orian-Rousseau, V; Ponta, H; Sansom, O; Schwager, C; Shatirishvili, M; Tawk, B; Warth, A	1
Ha, SY; Heo, JS; Kim, HC; Kim, KM; Kim, ST; Lauwers, G; Lee, J; Park, C; Park, YS	1
Allen, E; Hanahan, D; Li, L; Miéville, P; Peng, MW; Saghafinia, S; Warren, CM	1
Angulo-Urarte, A; Baselga, J; Casanovas, O; Castel, P; Figueiredo, AM; Graupera, M; Martin, L; Milà-Guasch, M; Monelli, E; Soler, A; Viñals, F	1
Bray, M; Cao, PM; Hedley, DW; Lohse, I; Mason, J; Pintilie, M	1
Philip, PA	1
Bajetta, E; Barone, C; Bycott, P; Chodkiewicz, C; Kim, S; Létourneau, R; Liau, K; Maurel, J; Pithavala, Y; Ricart, AD; Rixe, O; Spano, JP; Trask, P; Wasan, H; Wong, R	1
Barone, C; Chodkiewicz, C; Kim, S; Maurel, J; Ricart, AD; Rosbrook, B; Spano, JP; Springett, GM; Wasan, HS; Wong, R	1
Kelly, RJ; Rixe, O	1
Greten, TF; Manns, MP; Plentz, RR	1
Gou, S; Liu, T; Wang, C; Wang, L; Wang, T; Zhou, W	1
Bennouna, J; Bycott, P; Funakoshi, A; Furuse, J; Ioka, T; Kim, S; Kindler, HL; Létourneau, R; Ohkawa, S; Okusaka, T; Park, YS; Ricart, AD; Richel, DJ; Springett, GM; Trask, PC; Van Cutsem, E; Wasan, HS	1
Alì, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Di Paolo, A; Fioravanti, A; Fontanini, G; Orlandi, P	1
Kim, S; Moore, MJ; Pithavala, YK; Ricart, AD; Rixe, O; Spano, JP	1
B Cohen, R; Olszanski, AJ; Patson, B	1
Halfdanarson, TR; Naraev, BG; Strosberg, JR	1
Bentires-Alj, M; Brachmann, SM; Elain, G; Hofmann, F; Hofmann, I; Lai, A; Maira, SM; Roberts, TM; Romanet, V; Schmelzle, T; Schwaederle, M; Sellers, WR; Sterker, D; Weiss, A	1
Adhikari, LJ; Ames, MM; Gilbert, JA; Halfdanarson, TR; Lloyd, RV; Muders, MH	1
Anderson, KD; Davis, RB; Gowen, LC; Hashizume, H; Haskell, A; Joho, S; Kamba, T; Kuo, CJ; Mancuso, MR; McDonald, DM; Norberg, SM; O'Brien, SM; Sennino, B; Springer, ML; Tam, BY; Thurston, G	1
Arap, W; Chanthery, YH; Kasman, IM; McDonald, DM; Ozawa, MG; Pasqualini, R; Varner, AS; Yao, VJ	1
Han, H; Von Hoff, DD; Wang, H	1
Du, J; Gu, H; Liu, NZ; Qin, H; Teng, XL; Zhao, Q	1
Du, J; Gu, H; Liu, N; Qin, H; Teng, X; Zhang, Q; Zhao, Q	1
Kibble, A	1
Askenazy, N; Kaplan, O; Knubovets, T; Kushnir, T; Navon, G	1
Aldous, S; Corbett, TH; Coughlin, SA; Huang, JI; Jones, JL; Klingbeil, KM; Mattes, KC; Perni, RB; Peverly, AD; Powles, RG; Rake, JB; Robinson, RG; Wentland, MP	1

Reviews

6 review(s) available for indazoles and Cancer of Pancreas

Article	Year
[Homologous recombination deficiency and PARP inhibitors in therapeutics]. Bulletin du cancer, 2022, Volume: 109, Issue:1 Topics: Breast Neoplasms; DNA Damage; DNA Repair-Deficiency Disorders; Drug Resistance, Neoplasm; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Indoles; Male; Ovarian Neoplasms; Pancreatic Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Recombinational DNA Repair	2022
[NTRK Fusions: A new way of treatment for gastro-intestinal tumor?] Bulletin du cancer, 2020, Volume: 107, Issue:4 Topics: Benzamides; Colorectal Neoplasms; Gastrointestinal Neoplasms; Gene Fusion; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization; Indazoles; Membrane Glycoproteins; Nerve Growth Factors; Oncogene Proteins; Oncogene Proteins, Fusion; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor, trkA; Receptor, trkB; Receptor, trkC	2020
Axitinib (AG-013736). Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2010, Volume: 184 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Biological Availability; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Imidazoles; Indazoles; Neoplasms; Pancreatic Neoplasms; Thyroid Neoplasms	2010
Molecular therapy of pancreatic cancer. Minerva endocrinologica, 2010, Volume: 35, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A	2010
Pharmacokinetic evaluation of axitinib. Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:2 Topics: Animals; Axitinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Pancreatic Neoplasms; Protein Kinase Inhibitors; Thyroid Neoplasms	2012
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology, 2012, Volume: 83, Issue:3 Topics: Antineoplastic Agents; Benzenesulfonates; Cell Differentiation; ErbB Receptors; Everolimus; Histone Deacetylases; Humans; Immunologic Factors; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Somatostatin; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012

Trials

11 trial(s) available for indazoles and Cancer of Pancreas

Article	Year
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. The Lancet. Oncology, 2022, Volume: 23, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hypertension; Immune Checkpoint Inhibitors; Indazoles; Ipilimumab; Nivolumab; Pancreatic Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors	2022
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. British journal of cancer, 2013, Apr-30, Volume: 108, Issue:8 Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate	2013
Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours. British journal of cancer, 2013, Sep-17, Volume: 109, Issue:6 Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Indazoles; Intestinal Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrimidines; Stomach Neoplasms; Sulfonamides; Survival Rate; Treatment Outcome; Young Adult	2013
Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial. Japanese journal of clinical oncology, 2015, Volume: 45, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Deoxycytidine; Disease-Free Survival; European Union; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Japan; Kaplan-Meier Estimate; Male; Middle Aged; North America; Odds Ratio; Pancreatic Neoplasms; Treatment Outcome	2015
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. The Lancet. Oncology, 2015, Volume: 16, Issue:6 Topics: Aged; Carcinoid Tumor; Cohort Studies; Disease-Free Survival; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Outcome	2015
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Cells, Circulating; Neuroendocrine Tumors; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Proportional Hazards Models; Pyrimidines; Sulfonamides; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3	2015
Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours. British journal of cancer, 2015, Sep-01, Volume: 113, Issue:5 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Pancreatic Neoplasms; Pyrimidines; Sulfonamides; Topotecan; Treatment Outcome; Young Adult	2015
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet (London, England), 2008, Jun-21, Volume: 371, Issue:9630 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Axitinib; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Receptors, Vascular Endothelial Growth Factor; Survival Rate	2008
CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. British journal of cancer, 2009, Oct-06, Volume: 101, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Diastole; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pancreatic Neoplasms	2009
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. The Lancet. Oncology, 2011, Volume: 12, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis	2011
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Investigational new drugs, 2012, Volume: 30, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms	2012

Other Studies

36 other study(ies) available for indazoles and Cancer of Pancreas

Article	Year
Case report of oxalate nephropathy in a patient with pancreatic metastases from renal carcinoma. BMC cancer, 2019, Oct-17, Volume: 19, Issue:1 Topics: Acetates; Aged, 80 and over; Calcium Compounds; Carcinoma, Renal Cell; Exocrine Pancreatic Insufficiency; Gastrointestinal Agents; Humans; Indazoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Oxalates; Pancreatic Neoplasms; Pancrelipase; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis; Sulfonamides; Treatment Outcome	2019
A case of alveolar rhabdomyosarcoma showing concurrent responsive bone marrow lesions and refractory pancreatic lesions to pazopanib monotherapy. Pediatric blood & cancer, 2020, Volume: 67, Issue:9 Topics: Adolescent; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Neoplasms; Fluorodeoxyglucose F18; Forkhead Box Protein O1; Humans; Indazoles; Oncogene Proteins, Fusion; Paired Box Transcription Factors; Pancreatic Neoplasms; PAX3 Transcription Factor; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Rhabdomyosarcoma, Alveolar; Sulfonamides; Tumor Microenvironment; Zoledronic Acid	2020
Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell reports, 2020, 08-04, Volume: 32, Issue:5 Topics: Animals; Apoptosis; Bcl-2-Like Protein 11; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Female; HEK293 Cells; Humans; Indazoles; Lung Neoplasms; Male; Mice, Inbred NOD; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Receptor, trkA	2020
SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition. Biochemical and biophysical research communications, 2021, 05-07, Volume: 552 Topics: Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Indazoles; Mass Spectrometry; Mitogen-Activated Protein Kinase Kinases; Oxadiazoles; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proteome; Proteomics; Signal Transduction; Sulfonamides	2021
Survival of pancreatic cancer cells lacking KRAS function. Nature communications, 2017, 10-23, Volume: 8, Issue:1 Topics: Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Pancreatic Ductal; DNA Copy Number Variations; Humans; Immunoblotting; Indazoles; Mice; Morpholines; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins p21(ras); Purines; Pyrimidines; Pyrimidinones; Quinazolinones; Sulfonamides; Thiazoles	2017
LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma. Journal of pharmacological sciences, 2018, Volume: 137, Issue:2 Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Survival; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Indazoles; Neoplasm Invasiveness; Pancreatic Neoplasms; Piperazines; RNA, Long Noncoding	2018
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report. BMC nephrology, 2019, 01-03, Volume: 20, Issue:1 Topics: Aged; Amlodipine; Angiogenesis Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Diabetic Nephropathies; Dihydropyridines; Drug Substitution; Edema; Everolimus; Humans; Hypertension; Indazoles; Kidney Failure, Chronic; Lung Neoplasms; Male; Nephrotic Syndrome; Nivolumab; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pneumonectomy; Protein Kinase Inhibitors; Pyrimidines; Sirolimus; Sulfonamides; Sunitinib	2019
Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis. Journal of experimental & clinical cancer research : CR, 2019, May-27, Volume: 38, Issue:1 Topics: Animals; Autophagy; Carcinoma, Pancreatic Ductal; Cell Communication; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chloroquine; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Indazoles; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Metastasis; Pancreatic Neoplasms; Pancreatic Stellate Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Stromal Cells; Xenograft Model Antitumor Assays	2019
Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer cell, 2013, Mar-18, Volume: 23, Issue:3 Topics: 3-Phosphoinositide-Dependent Protein Kinases; Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase Inhibitor p16; Enzyme Activation; Humans; Indazoles; Lithostathine; Metaplasia; Mice; Mice, Inbred NOD; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Signal Transduction; Sulfonamides; TNF Receptor-Associated Factor 3; Transplantation, Heterologous; Tumor Cells, Cultured	2013
Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models. Molecular cancer therapeutics, 2013, Volume: 12, Issue:6 Topics: Aniline Compounds; Apoptosis; bcl-X Protein; Cell Line, Tumor; Enzyme Inhibitors; Genes, bcl-2; Humans; Indazoles; Lung Neoplasms; MAP Kinase Kinase Kinases; Molecular Targeted Therapy; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Sulfonamides	2013
Activated PAR-2 regulates pancreatic cancer progression through ILK/HIF-α-induced TGF-α expression and MEK/VEGF-A-mediated angiogenesis. The American journal of pathology, 2013, Volume: 183, Issue:2 Topics: Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Down-Regulation; Flavonoids; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Receptor, PAR-2; RNA, Small Interfering; Signal Transduction; Transforming Growth Factor alpha; Up-Regulation; Vascular Endothelial Growth Factor A	2013
Role of autophagy in apoptotic regulation by Akt in pancreatic cancer. Anticancer research, 2014, Volume: 34, Issue:2 Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Autophagy; Caspases; Cell Line, Tumor; Enzyme Activation; Humans; Indazoles; Indoles; Microscopy, Fluorescence; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases	2014
Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma. Cell death & disease, 2014, Apr-10, Volume: 5 Topics: Adenocarcinoma; Animals; Axitinib; Cell Membrane; Cell Proliferation; Cell Shape; Cell Survival; Clone Cells; Drug Resistance, Neoplasm; Enzyme Activation; G2 Phase Cell Cycle Checkpoints; Glucose; Glucose Transporter Type 1; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Indazoles; Mice; Mitosis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt	2014
Bespoke treatment: drivers beware! Asia-Pacific journal of clinical oncology, 2014, Volume: 10, Issue:4 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fatal Outcome; Female; Humans; Indazoles; Liver Neoplasms; Microtubule-Associated Proteins; Middle Aged; Molecular Targeted Therapy; Mutation; Oncogenes; Pancreatic Neoplasms; Paraneoplastic Syndromes; Pyrimidines; Radiography; Receptor, Fibroblast Growth Factor, Type 3; Sulfonamides	2014
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer. Molecular cancer therapeutics, 2015, Volume: 14, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Indazoles; MAP Kinase Kinase 1; Mice; Models, Biological; Mutation; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Standard of Care; Sulfonamides; Xenograft Model Antitumor Assays	2015
Oncotropic H-1 parvovirus infection degrades HIF-1α protein in human pancreatic cancer cells independently of VHL and RACK1. International journal of oncology, 2015, Volume: 46, Issue:5 Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; GTP-Binding Proteins; H-1 parvovirus; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Neoplasm Proteins; Oncolytic Virotherapy; Pancreatic Neoplasms; Parvoviridae Infections; Receptors for Activated C Kinase; Receptors, Cell Surface; Reverse Transcriptase Polymerase Chain Reaction; Von Hippel-Lindau Tumor Suppressor Protein	2015
Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU international, 2016, Volume: 117, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome	2016
Symptomatic cardiac metastasis responding to pazopanib in a patient with renal cell carcinoma. The Canadian journal of urology, 2015, Volume: 22, Issue:3 Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Heart Neoplasms; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Pyrimidines; Sulfonamides; Watchful Waiting	2015
Inhibition of Tumor Growth and Metastasis in Pancreatic Cancer Models by Interference With CD44v6 Signaling. Gastroenterology, 2016, Volume: 150, Issue:2 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Crizotinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Hyaluronan Receptors; Indazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mice, Nude; Mice, Transgenic; Mutation; Neoplasm Metastasis; Pancreatic Neoplasms; Peptides; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Rats; RNA, Messenger; Signal Transduction; Sulfonamides; Time Factors; Transfection; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2016
Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. Oncotarget, 2016, Jan-26, Volume: 7, Issue:4 Topics: Adult; Aged; Biomarkers, Tumor; Cohort Studies; Exome; Female; Genome, Human; High-Throughput Nucleotide Sequencing; Humans; Indazoles; Intestinal Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins B-raf; Pyrimidines; Stomach Neoplasms; Sulfonamides	2016
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell reports, 2016, 05-10, Volume: 15, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glucose; Glutamine; Glycolysis; Humans; Imidazoles; Indazoles; Indoles; Intestinal Neoplasms; Lactic Acid; Membrane Transport Proteins; Mice; Models, Biological; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sirolimus; Stomach Neoplasms; Sunitinib; TOR Serine-Threonine Kinases; Up-Regulation	2016
Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Dec-01, Volume: 22, Issue:23 Topics: Animals; Antineoplastic Agents; Benzoxepins; Cell Line, Tumor; Cell Proliferation; Everolimus; Humans; Imidazoles; Indazoles; Liver; Lymphatic Metastasis; Mice; Mice, Inbred C57BL; Neuroendocrine Tumors; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays	2016
Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts. Oncotarget, 2017, Jan-10, Volume: 8, Issue:2 Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Immunohistochemistry; Indazoles; Indoles; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays	2017
Targeting angiogenesis in pancreatic cancer. Lancet (London, England), 2008, Jun-21, Volume: 371, Issue:9630 Topics: Angiogenesis Inhibitors; Axitinib; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Imidazoles; Indazoles; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor	2008
Insulin promotes proliferative vitality and invasive capability of pancreatic cancer cells via hypoxia-inducible factor 1alpha pathway. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2010, Volume: 30, Issue:3 Topics: Cell Line, Tumor; Cell Proliferation; Guanylate Cyclase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Insulin; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA, Messenger; Signal Transduction	2010
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. Neoplasia (New York, N.Y.), 2011, Volume: 13, Issue:3 Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Axitinib; Blotting, Western; Camptothecin; Cation Transport Proteins; Cell Proliferation; Cells, Cultured; Copper-Transporting ATPases; Drug Synergism; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunoenzyme Techniques; Indazoles; Irinotecan; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thrombospondins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2011
K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PloS one, 2012, Volume: 7, Issue:8 Topics: Animals; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Knockdown Techniques; HEK293 Cells; Humans; Indazoles; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Mutation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); ras Proteins; Sulfonamides; Xenograft Model Antitumor Assays	2012
Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. Pancreas, 2013, Volume: 42, Issue:3 Topics: Axitinib; Benzoquinones; Biomarkers, Tumor; Carcinoid Tumor; Cell Line, Tumor; Cell Survival; Drug Therapy; ErbB Receptors; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Immunohistochemistry; In Situ Hybridization, Fluorescence; Indazoles; Lactams, Macrocyclic; Mutation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins p21(ras); Pyrazoles; ras Proteins; Receptor, ErbB-2; Receptor, IGF Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Transforming Growth Factor-beta Type I; Receptors, Somatostatin; Receptors, Transforming Growth Factor beta; Triazines; Vascular Endothelial Growth Factor Receptor-1	2013
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. American journal of physiology. Heart and circulatory physiology, 2006, Volume: 290, Issue:2 Topics: Aging; Animals; Axitinib; Blood Pressure; Capillaries; Carcinoma, Lewis Lung; Glucose Tolerance Test; Heart; Imidazoles; Indazoles; Islets of Langerhans; Kidney; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Transplantation; Pancreatic Neoplasms; Phenotype; Reference Values; Regeneration; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2	2006
Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. Cancer research, 2006, Mar-01, Volume: 66, Issue:5 Topics: Adenoma, Islet Cell; Animals; Axitinib; Bacteriophage M13; Endothelial Cells; Female; Imidazoles; Indazoles; Integrin alpha5beta1; Integrin alphaVbeta3; Male; Mice; Mice, Transgenic; Microscopy, Fluorescence; Neovascularization, Pathologic; Oligopeptides; Pancreatic Neoplasms; Substrate Specificity	2006
Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Cancer research, 2006, Oct-01, Volume: 66, Issue:19 Topics: Adenocarcinoma; Anthraquinones; Antineoplastic Agents; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin B; Drug Screening Assays, Antitumor; Feasibility Studies; Fibroblasts; G2 Phase; Gene Expression Profiling; Humans; Indazoles; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; S Phase; Smad4 Protein	2006
[Inhibitory effect of YC-1 on induction of VEGF and GPI genes in hypoxic human pancreatic cancer cells]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2006, Volume: 28, Issue:7 Topics: Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Enzyme Activators; Gene Expression Regulation, Neoplastic; Glucose-6-Phosphate Isomerase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Vascular Endothelial Growth Factors	2006
Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells. Pancreas, 2007, Volume: 34, Issue:2 Topics: Apoptosis; Cell Division; Cell Hypoxia; Cell Line, Tumor; Enzyme Activators; Gene Expression Regulation, Neoplastic; Glucose-6-Phosphate Isomerase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Oxygen; Pancreatic Neoplasms; RNA, Messenger; Transcription, Genetic; Vascular Endothelial Growth Factor A	2007
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3. IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome	2007
Role of nuclear magnetic resonance spectroscopy (MRS) in cancer diagnosis and treatment: 31P, 23Na, and 1H MRS studies of three models of pancreatic cancer. Cancer research, 1997, Apr-15, Volume: 57, Issue:8 Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma, Papillary; Animals; Antineoplastic Agents; Carcinogens; Cricetinae; Deoxyglucose; Humans; Indazoles; Magnetic Resonance Spectroscopy; Male; Mesocricetus; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorus; Protons; Rats; Rats, Sprague-Dawley; Sodium; Tumor Cells, Cultured	1997
Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives. Journal of medicinal chemistry, 1998, Sep-10, Volume: 41, Issue:19 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; DNA, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Indazoles; Intercalating Agents; Leukemia P388; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Pyrans; Structure-Activity Relationship; Thioxanthenes; Topoisomerase II Inhibitors; Tumor Cells, Cultured	1998